Green Tea Combined With Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer

Condition:   Non-small Cell Lung Cancer Intervention:   Other: green tea Sponsors:   Xinqiao Hospital of Chongqing;   Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Authors: Alexander M, Ko B, Lambert R, Gadgeel S, Halmos B Abstract Introduction: The immune checkpoint inhibitor, pembrolizumab, has revolutionized the treatment of non-small cell lung cancer (NSCLC). It is currently approved in patients with advanced NSCLC whose tumors have no EGFR or ALK genomic aberrations that express PD-L1 in the first line setting.Areas covered: The authors have reviewed articles discussing pembrolizumab and NSCLC in MEDLINE between July 2013 to August 2019 and focus on recent advances in combining pembrolizumab with chemotherapy, radiotherapy and other novel agents in various stages of NSCL...
Source: Expert Review of Respiratory Medicine - Category: Respiratory Medicine Tags: Expert Rev Respir Med Source Type: research
In this study, we found that glucose-6-phosphate dehydrogenase (G6PD), a critical enzyme of the pentose phosphate pathway, contributed to cisplatin resistance in NSCLC. The experimental results showed that transforming growth factor beta 1 (TGFβ1) increased the expression of G6PD by activating the forkhead box protein M1-high mobility group AT-hook 1-G6PD (FOXM1-HMGA1-G6PD) transcriptional regulatory pathway, in which TGFβ1 inhibited the ubiquitination and degradation of FOXM1 protein. Additionally, HMGA1 induced TGFβ1 expression, and neutralized TGFβ1 in the culture medium downregulated HMGA1 levels, s...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
Publication date: Available online 10 December 2019Source: Respiratory Medicine Case ReportsAuthor(s): Keima Ito, Tetsuya Oguri, Norihisa Takeda, Kensuke Fukumitsu, Satoshi Fukuda, Yoshihiro Kanemitsu, Tomoko Tajiri, Hirotsugu Ohkubo, Masaya Takemura, Ken Maeno, Yutaka Ito, Akio NiimiAbstractA 76-year-old man was admitted to our hospital with cough and dyspnea. He was diagnosed with advanced lung cancer. Nivolumab was given as second-line treatment, cytotoxic chemotherapy was given as third-line treatment, and nivolumab re-challenge was given as fourth-line treatment. Thereafter, 41 chemotherapy courses were administered o...
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
Authors: Nobili S, Lavacchi D, Perrone G, Vicini G, Tassi R, Landini I, Grosso A, Roviello G, Mazzanti R, Santomaggio C, Mini E Abstract The use of vinorelbine as single agent or in combination regimens in NSCLC is associated with satisfactory clinical activity. However, the role of vinorelbine-based chemotherapy in chemonaive locally advanced unresectable or metastatic NSCLC patients, according to real-world treatment patterns, has still not widely explored. Eighty-one patient treated at a single institution were retrospectively analyzed. Thirty-seven received standard first-line single-agent vinorelbine, 44 vinor...
Source: Oncology Research - Category: Cancer & Oncology Tags: Oncol Res Source Type: research
Authors: Jankowska-Polańska B, Polański J, Chabowski M, Rosińczuk J, Mazur G Abstract The purpose of this study was to evaluate the influence of cognitive adjustment to cancer, assessed on the mini-Mental Adjustment to Cancer (mini-MAC) scale, on perception of anxiety and depression, assessed with the Hospital Anxiety and Depression Scale, in patients with non-small cell lung carcinoma (NSCLC). There were 185 patients, grouped according to the score of mini-MAC into constructive coping strategies, balanced coping strategies, and destructive coping strategies. We found that patients with predominantly destructive...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Authors: Liao Y, Wang X, Zhong P, Yin G, Fan X, Huang C Abstract As a malignant tumor with poor prognosis, accurate and effective treatment of non-small cell lung cancer (NSCLC) is crucial. To predict overall survival in patients with stage II and III NSCLC, a nomogram was constructed using data from the Surveillance, Epidemiology and End Results database. Eligible patients with NSCLC with available clinical information diagnosed between January 1, 2010 and November 31, 2015 were selected from the database, and the data were randomly divided into a training set and a validation set. Univariate and multivariate Cox ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Roche today announced that the US Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) in combination with chemotherapy (Abraxane® [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) for the initial (first-line) treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
The FDA approved atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer with no  EGFR or ALK genomic tumor aberrations.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
South San Francisco, CA -- December 3, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) in combination with chemotherapy...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
ConclusionsPolymorphisms of theTOP2A andERCC1 genes may be a predictive factor of toxicities and survival for chemotherapy in NSCLC patients.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Green Tea | Hospitals | Lung Cancer | Non-Small Cell Lung Cancer | Research